Summary of Study ST001140

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000761. The data can be accessed directly via it's Project DOI: 10.21228/M89Q32 This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

Study ID	ST001140
Study Title	Changes in the Canine Plasma Lipidome after Short- and Long-Term Excess Glucocorticoid Exposure
Study Summary	Glucocorticoids (GCs) are widely used in veterinary and human medicine. Chromic endogenous or iatrogenic GC overexposure impairs metabolic function and can result in diverse side-effects, including Cushing’s syndrome. This study examines the effects of experimentally induced short-term and long-term GC excess (induced by prednisolone and tetracosactide, respectively) on the plasma lipidome of Beale dogs. Both, long- and short-term GC resulted in significant changes of the plasma lipidome.
Institute	National University of Singapore;University of Zurich
Department	Singapore Lipidomics Incubator (SLING);Vetsuisse Faculty, University of Zurich
Laboratory	Singapore Lipidomics Incubator (SLING), National University of Singapore
Last Name	Burla
First Name	Bo
Address	28 Medical Drive, Singapore 117456, Singapore
Email	bo.burla@nus.edu.sg
Phone	+6565166683
Submit Date	2019-01-19
Num Groups	2
Total Subjects	14
Num Males	9
Num Females	5
Raw Data Available	Yes
Raw Data File Type(s)	d
Analysis Type Detail	LC-MS
Release Date	2019-03-06
Release Version	1

Select appropriate tab below to view additional metadata details:

Treatment:

Treatment ID:	TR001219
Treatment Summary:	In the short-term prednisolone group, dogs were treated with 50 mg prednisolone (Streuli Pharma AG, Switzerland) orally twice daily for 3 consecutive days. For the long-term tetracosactide treatment, ALZET osmotic pumps (Durect Corporation, USA) subcutaneously delivering tetracosactide (synthetic ACTH; Bachem AG, Switzerland) were implanted into the dorsolateral neck. New pumps were implanted every 4 weeks. Total infusion time was 25 weeks, with a starting dose of 1.3–1.95 µg/kg/d tetracosactide, which was gradually increased to a final dose of 6–10 µg/kg/d.

Treatment ID:

TR001219

Treatment Summary:

In the short-term prednisolone group, dogs were treated with 50 mg prednisolone (Streuli Pharma AG, Switzerland) orally twice daily for 3 consecutive days. For the long-term tetracosactide treatment, ALZET osmotic pumps (Durect Corporation, USA) subcutaneously delivering tetracosactide (synthetic ACTH; Bachem AG, Switzerland) were implanted into the dorsolateral neck. New pumps were implanted every 4 weeks. Total infusion time was 25 weeks, with a starting dose of 1.3–1.95 µg/kg/d tetracosactide, which was gradually increased to a final dose of 6–10 µg/kg/d.